Diffuse large B-cell lymphoma and treatment advances for diffuse large B-cell lymphoma are described further in this issue of Nature Outlook: Lymphoma. Immunotherapies for non-Hodgkin lymphoma and ...

A research team led by Prof. Gu Hongcang from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

From today, adults with advanced Hodgkin lymphoma have access to a new treatment, after we recommended brentuximab vedotin (brand name Adcetris) in combination with other therapies for routine NHS use ...

NICE has made 97 positive recommendations for blood cancer treatments over the last decade, five times more than in the previous ten years. 92% of blood cancer treatment recommendations since 2015 ...

The specific treatment course and prognosis for T-cell lymphoma depends on the subtype — of which there are many — and how advanced the cancer is. Hodgkin lymphoma involves a type of cancer ...

A new treatment for Hodgkin lymphoma has been recommended for routine use on the NHS. Around 800 people with the advanced form of blood cancer could benefit, it is believed. The condition develops ...

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

Investigators have uncovered how resistance to chemotherapies may occur in some cancers. Researchers focused on a pathway that harnesses reactive oxygen species (ROS) to kill cancer cells. The study ...

The FDA has accepted and begun its review of odronextamab for relapsed or refractory follicular lymphoma (FL ... therapies move earlier in the treatment pathway.